Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s. · BIST:ECILC

Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s — Eczacıbaşı Pharmaceutical and Industrial Investment — Shareholder Meeting (April 2020)

20 slides from Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s's shareholder meeting presentation, Apr 9, 2020

1. Slide 1: Ordinary General Assembly Meeting 9 April 2020

   EİS ECZACIBAŞI PHARMACEUTICAL AND INDUSTRIAL INVESTMENT CO. ORDINARY GENERAL ASSEMBLY MEETING 9 APRIL 2020

2. Slide 2: Table of Contents

   TABLE OF CONTENTS  General Information  Activity Information  Consolidated  Health  Real Estate Development  Future Strategies  BIST Indicators

3. Slide 3: General Information

    General Information  Shareholding Structure  Affiliates and Partnerships  Existing Consolidated Structure

4. Slide 4: Shareholding Structure

   SHAREHOLDING STRUCTURE SHAREHOLDING SHARE NAME OF THE SHAREHOLDER RATIO AMOUNT (TL) (%) ECZACIBAŞI HOLDİNG A.Ş. 346,845,460 50.62 ECZACIBAŞI YATIRIM HOLDİNG ORT. A.Ş. 203,294,584 29.67 PUBLIC SHAREHOLDERS (Out-of-Group Shares) 135,119,955 19.71 TOTAL 685,260,000 100.00

5. Slide 5: Affiliates and Partnerships

   AFFILIATES AND PARTNERSHIPS NOMINAL SHAREHOLDING SHAREHOLDING CAPITAL RATIO AMOUNT (TL) (% ) (TL) SUBSIDIARIES EİP Eczacıbaşı İlaç Pazarlama A.Ş. 99.9 56,055,120 56,100,000 Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş. 99.5 2,487,353 2,500,000 Eczacıbaşı İlaç Ticaret A.Ş. 94.7 47,350 50,000 JOIN

6. Slide 6: Existing Consolidated Structure

   EXISTING CONSOLIDATED STRUCTURE ECILC Health Real Estate Development Other (Partnerships and Activities) • Ecz. İlaç Pazarlama %99.9 • Ecz. Holding %37.3 • Ecz. Gayrimenkul A.Ş. %99.5 • Ecz. İlaç Ticaret %99.8 • Ecz. Dış Ticaret %26,4 • Kanyon Ofis %100 • Tasfiye Hal. Ecz.-Baxter %50 • Vitra Karo %2

7. Slide 7: Activity Information

    Activity Information  Consolidated  Health  Real Estate Development

8. Slide 8: Consolidated Indicators for 2018-2019

   CONSOLIDATED INDICATORS FOR 2018- 2019 (TL MILLION) 2018 2019 ∆ (%)  Consolidated Total Assets: 4,456 4,838 8.6  Consolidated Total Equity: 3,998 4,277 7.0

9. Slide 9: Consolidated Indicators for 2018-2019

   CONSOLIDATED INDICATORS FOR 2018- 2019 (TL MILLON) 2018 877 2019 900 692 300 750 240 600 163 200 450 300 100 150 0 0 CONSOLIDATED CONSOLIDATED REVENUE PROFIT FOR THE PERIOD

10. Slide 10: 2019 Financial Data on Subsidiaries, Affiliates, and Joint Ventures

    2019 FINANCIAL DATA ON SUBSIDIARIES, AFFILIATES, AND JOINT VENTURES Net Income / Direct Operating Loss for the Shareholding Capital Assets Equity Revenue Profit / Loss Period As of 31 December 2019 (*) Ratio (%) (TL) (TL Thousand) (TL Thousand) (TL Thousand) (TL Thousand) (TL Thousand) Subsidiaries

11. Slide 11: 2019 Consolidated Segment Developments - Health

    2019 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - MATERIAL DEVELOPMENTS IN THE SECTOR  According to the IMS data, the Turkish Pharmaceutical Market grew by 32.2% on TL basis and reached TL 32.5 billion in 2019.  In line with the localization policy included in the action plans of the Government fo

12. Slide 12: 2019 Consolidated Segment Developments - Health

    2019 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı İlaç Pazarlama  Eczacıbaşı İlaç Pazarlama enhances its collaborations in 3 main fields of activity with a focus on constant development:  The company entered the field of Oncology Therapy, one of fastest-growin

13. Slide 13: 2019 Consolidated Segment Developments - Health

    2019 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Nuclear Medicine Eczacıbaşı - Monrol  In 2019, overseas businesses were expanded, new business operations were started in Pakistan.  With a focus on increased export, we recorded an increase at about 50% on a Euro basis.

14. Slide 14: 2019 Consolidated Segment Developments - Health

    2019 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES  Eczacıbaşı Sağlık Hizmetleri A.Ş. Eczacıbaşı Sağlık Hizmetleri A.Ş. was sold to an individual investor, in its entirety, for TL 630,000 on 2 March 2020. Share transfer transactions were completed on the same day and the e

15. Slide 15: 2019 Consolidated Segment Developments - Real Estate Development

    2019 CONSOLIDATED SEGMENT DEVELOPMENTS - REAL ESTATE DEVELOPMENT - KANYON  We focused on events and projects that could make a difference at Kanyon where EİS owns 100% of the office block and 50% of the Mall given weakening in the retail sector, the increase in competition and in order to minimize

16. Slide 16: Future Strategies

     Future Strategies

17. Slide 17: Future Strategies

    FUTURE STRATEGIES HEALTH  It is aimed to keep pace with developments emerging in the healthcare sector,  To expand the portfolio of Rare Diseases, Oncology, Vitamin-Mineral and Supplements,  To increase overseas operations in the field of nuclear medicine,  To grow in the field of Nuclear Medici

18. Slide 18: BIST Indicators

     BIST Indicators

19. Slide 19: ECILC - BIST100 Performance Summary (2019 year)

    ECILC - BIST100 PERFORMANCE SUMMARY (2019 year)

20. Slide 20: Thank You

    > THANK YOU ... —/,

Eczacıbaşı Pharmaceutical and Industrial Investment — Shareholder Meeting (April 2020) on 6ix